The Loss of Respiratory Syncytial Virus Seasonality and the Effects on Palivizumab Administration

Pediatr Infect Dis J. 2022 Sep 1;41(9):e407-e408. doi: 10.1097/INF.0000000000003616. Epub 2022 Jun 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Humans
  • Infant
  • Palivizumab / therapeutic use
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus, Human*

Substances

  • Antiviral Agents
  • Palivizumab